CN115368239A - 一种肉桂酸酯衍生物的合成及其制药应用 - Google Patents
一种肉桂酸酯衍生物的合成及其制药应用 Download PDFInfo
- Publication number
- CN115368239A CN115368239A CN202211067689.0A CN202211067689A CN115368239A CN 115368239 A CN115368239 A CN 115368239A CN 202211067689 A CN202211067689 A CN 202211067689A CN 115368239 A CN115368239 A CN 115368239A
- Authority
- CN
- China
- Prior art keywords
- carbon atoms
- cancer
- substituted
- unsaturated
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 9
- 238000003786 synthesis reaction Methods 0.000 title claims description 9
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical class [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 title abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 201000011510 cancer Diseases 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 208000011571 secondary malignant neoplasm Diseases 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 53
- 229920006395 saturated elastomer Polymers 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- -1 t-butoxycarbonyl Chemical group 0.000 claims description 26
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 18
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 16
- 230000003833 cell viability Effects 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000004614 tumor growth Effects 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000005561 phenanthryl group Chemical group 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000004973 liquid crystal related substance Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 150000001350 alkyl halides Chemical class 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 41
- 238000011282 treatment Methods 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 11
- 210000004072 lung Anatomy 0.000 abstract description 2
- 210000001072 colon Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 31
- 229940114081 cinnamate Drugs 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 22
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000012544 monitoring process Methods 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 229940126543 compound 14 Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 9
- 229940125904 compound 1 Drugs 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 235000013985 cinnamic acid Nutrition 0.000 description 8
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 8
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 229930016911 cinnamic acid Natural products 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- OKVJCVWFVRATSG-UHFFFAOYSA-N 3-hydroxybenzyl alcohol Chemical compound OCC1=CC=CC(O)=C1 OKVJCVWFVRATSG-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VKRWRNVGVPSVLA-UHFFFAOYSA-N n,n'-bis(2-phenylphenyl)oxamide Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1NC(=O)C(=O)NC1=CC=CC=C1C1=CC=CC=C1 VKRWRNVGVPSVLA-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- UFSPIRAYZHITQO-UHFFFAOYSA-N [3-(3-fluorophenoxy)phenyl]methanol Chemical compound OCC1=CC=CC(OC=2C=C(F)C=CC=2)=C1 UFSPIRAYZHITQO-UHFFFAOYSA-N 0.000 description 2
- ZKZSJQJXKWKOJY-UHFFFAOYSA-N [3-(phenoxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC(COC=2C=CC=CC=2)=C1 ZKZSJQJXKWKOJY-UHFFFAOYSA-N 0.000 description 2
- WRWYGOVGIGCDLE-UHFFFAOYSA-N [O]c1ccccc1F Chemical group [O]c1ccccc1F WRWYGOVGIGCDLE-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 1
- FSWNRRSWFBXQCL-UHFFFAOYSA-N (3-bromophenyl)methanol Chemical compound OCC1=CC=CC(Br)=C1 FSWNRRSWFBXQCL-UHFFFAOYSA-N 0.000 description 1
- QDFKKJYEIFBEFC-UHFFFAOYSA-N 1-bromo-3-fluorobenzene Chemical compound FC1=CC=CC(Br)=C1 QDFKKJYEIFBEFC-UHFFFAOYSA-N 0.000 description 1
- HRZTZLCMURHWFY-UHFFFAOYSA-N 2-bromo-1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1Br HRZTZLCMURHWFY-UHFFFAOYSA-N 0.000 description 1
- PMYOJVWSJTZGDJ-UHFFFAOYSA-N 3-methoxy-5-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC(OC)=CC(C(O)=O)=C1 PMYOJVWSJTZGDJ-UHFFFAOYSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CKRZKMFTZCFYGB-UHFFFAOYSA-N N-phenylhydroxylamine Chemical compound ONC1=CC=CC=C1 CKRZKMFTZCFYGB-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- MMOPREBWKCZVPO-ZIKNSQGESA-N OC(=O)C=CC1=CC=C(O)C=C1.OC(=O)\C=C\C1=CC=C(O)C=C1 Chemical compound OC(=O)C=CC1=CC=C(O)C=C1.OC(=O)\C=C\C1=CC=C(O)C=C1 MMOPREBWKCZVPO-ZIKNSQGESA-N 0.000 description 1
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000215602 Pyronema Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N caffeic acid Chemical compound OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/65—Halogen-containing esters of unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
Abstract
Description
技术领域
本发明属于药物化合物技术领域,具体涉及一种肉桂酸酯衍生物结构、其制备方法及其抗肿瘤活性与制药应用。
背景技术
天然有机物酚酸是植物降解的产物,在植物中发现的两大类酚酸包括苯甲酸和肉桂酸(3-苯基丙烯酸)及其衍生物。最常见的肉桂羟基衍生物是对香豆酸(4-羟基肉桂酸)和咖啡酸(3,4-二羟基肉桂酸)。肉桂酸是莽草酸途径的关键中间产物,是类黄酮或木质素合成的前体。肉桂酸衍生物是植物的次生代谢产物,在植物的生长、发育、繁殖和抗病等方面发挥着重要作用。肉桂酸衍生物由于在植物中广泛存在,毒性低,生物活性高,被认为是食品添加剂或药理活性化合物。苯环上取代的丙烯酸基团使肉桂酸具有顺式(Z)或反式(E)构型,其中反式(E)构型最为常见,肉桂酸可通过苯丙氨酸的酶促脱氨反应制备。肉桂酸的结构如下:
肉桂酸衍生物在治疗癌症、细菌感染、糖尿病和神经系统疾病等方面的作用已被报道。除了天然存在于植物中的肉桂酸衍生物外,苯环和丙烯酸基团的存在使其修饰合成肉桂酸衍生物成为可能。肉桂酸衍生物不仅是二苯乙烯、苯乙烯等化合物的中间体,还具有抗肿瘤、抗菌、抗真菌、抗炎、神经保护和抗糖尿病等活性。已有文献报道的肉桂酸衍生物有阿魏酸咖啡酸绿原酸以及Deng等人从植物内生真菌Pyronema sp中提取的等。这些肉桂酸衍生物的结构修饰涉及苯环、丙烯基和羧基连接子等部分。据报道,与用于治疗慢性或传染病的标准药物相比,其中一些衍生物在体外更有效,因此使它们成为非常有前途的治疗药物。
肉桂酸衍生物的生物活性改变归因于取代基的性质和位置,例如苯环上取代基的性质和位置影响衍生物的抗菌、抗癌和抗氧化活性,羧基连接子的长度也影响衍生物的生物活性。常规治疗药物的耐药性和缺乏具有低副作用的治疗方法来控制肿瘤、微生物生长、神经系统疾病等现实因素推动了基于肉桂酸的治疗性化合物的开发研究。
发明内容
本发明提供了一种肉桂酸酯衍生物,其具有有价值的药理性质,特别是抑制肿瘤生长、加速细胞凋亡和抑制细胞活力。
本发明还进一步提供了所述肉桂酸酯衍生物的制备方法。
具有式I结构的化合物,或者其立体异构体、药物可接受的盐或多晶型:
其中:
R1为苯环上的氢或取代基,R1为取代基时可相同或不同,独立的选自单取代或多取代,R1独立的选自氢、卤素、1-4个碳原子的烷基、1-4个碳原子的烷氧基、1-4个碳原子的卤代烷烃、1-4个碳原子的烷苯基、0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
R2和R3相同或不同,独立的选自氢、未取代或取代的苯基、萘基、蒽基、菲基,其中的取代基被独立地选自卤素、1-4个碳原子的烷基、1-4个碳原子的烷氧基、1-4个碳原子的卤代烷烃、1-4个碳原子的烷苯基、0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
R4独立的选自氢、甲基、二取代甲基、三取代甲基、未取代或取代的1-4个碳原子的烷苯基、萘基、蒽基、菲基,其中1-4个碳原子的烷苯基、萘基、蒽基、菲基的取代基被独立地选自卤素、1-4个碳原子的烷基、1-4个碳原子的烷氧基、1-4个碳原子的卤代烷烃、1-4个碳原子的烷苯基、0-4个碳原子的烷氧苯基或卤素等取代的0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
优选,R1为苯环上的氢或取代基,R1为取代基时选自单取代或二取代,R1选自氢、1-4个碳原子的烷氧基、1-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
优选,R2和R3相同,均选自氢;
优选,R4选自三取代甲基、未取代的1-4个碳原子的烷苯基或取代的1-4个碳原子的烷苯基,其中取代基被独立地选自1-4个碳原子的烷基、1-4个碳原子的烷氧基、0-4个碳原子的烷氧苯基或卤素等取代的0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团。
在本发明的一个实施方案中,其中R1为苯环上的氢或取代基,R1为取代基时选自单取代或二取代,R1选自氢、甲氧基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团,R2和R3均选自氢,选自单键或双键,R4选自三取代甲基、未取代的1-4个碳原子的烷苯基或被独立地选自烷氧基、烷氧苯基或卤素等取代的烷氧苯基、哌啶基、吡啶基、叔丁氧羰基取代哌啶基或叔丁氧羰基取代吡啶基中的一个或更多个基团取代的1-4个碳原子的烷苯基,其具有式II结构:
表1
本发明还提供式I、II和III化合物的制备方法:式I、II和III中的部分化合物由左侧酸部分Ra进一步反应生成酰氯,然后与右侧醇部分Rb缩合而成,
根据本发明的示例性化合物中左侧酸部分Ra包括表2阐述的中间体化合物:
表2
中间体化合物Ra1和Ra2可以按照本领域已知的合成方法制备,例如:(Ra1)Inquest of small-molecules as potent non-competitive inhibitors againstinfluenza,Bioorg.Chem.,2021,114,105139;(Ra2)N-hydroxyphthalimide catalyzedaerobic oxidation of aldehydes under continuous flow conditions,AdvancedSynthesis&Catalysis,2022,364,1998-2008。
根据本发明的示例性化合物中右侧醇或胺部分包括表3阐述的中间体化合物:
表3
其中,中间体化合物Rb1~Rb8可按照本领域已知的合成方法制备,例如:(Rb4)CN109516914A,2019.03.26;(Rb7)Potent human glutaminyl cyclase inhibitors aspotential anti-Alzheimer’s agents:Structure-activity relationship study ofArg-mimetic region,Bioorgan.Med.Chem.,2018,26,1035-1049。
在本发明的一个实施方案中,化合物12和13的制备方法如下:
在本发明的一个实施方案中,化合物14、15和16的制备方法如下:
除特别说明之外,上述制备方法中已有文献报道的化合物均可以采用本领域已知的反应方法和条件进行。
本发明还提供一种药物组合物,其包含本发明的式I化合物或其溶剂化物作为活性成分,任选地还含有一种或多种药学上可接受的载体。所述药学上可接受的载体是制药领域中常用或已知的各种辅料,包括但不限于:稀释剂、粘合剂、抗氧化剂、pH调节剂、防腐剂、润滑剂、崩解剂等。
在本发明的一种实施方式中,所述药物组合物用于治疗或预防癌症,抑制肿瘤生长、加速细胞凋亡和抑制细胞活力。
根据本发明,所述癌症包括原发性和继发性癌症,包括但不限于肝癌、肺癌、淋巴癌和甲状腺癌等,优选,所述癌症为结肠癌。
所述药物组合物中含有式I化合物的量(以式I化合物计)为0.1-1000mg,优选1-500mg,更优选为5-100mg。
所述药物组合物中式I化合物(以式I化合物计)占药物组合物的质量百分比为0.01%-95%,根据剂型不同例如可以为0.1%-10%,0.3~5%,或者10%-90%,优选为20%-80%,更优选为30%-70%等含量范围。
所述药物组合物的剂型可以是口服剂的形式,例如片剂、胶囊、丸剂、粉剂、颗粒剂、悬浮剂、糖浆剂等;也可以是注射给药的剂型,例如注射液、粉针剂等,通过静脉内、腹膜内、皮下或肌肉内的途径注射给药。所有使用的剂型形式都是药学领域普通技术人员所熟知的。例如所述药物组合物可以为注射液,式I化合物在注射液中的浓度可以为1-15mg/ml,例如5mg/ml、10mg/ml、12.5mg/ml等。
所述药物组合物的施用途径包括但不限于:口服的;含服的;舌下的;透皮的;肺的;直肠的;肠胃外的,例如,通过注射,包括皮下的、真皮内的、肌内的、静脉内的;通过植入储库或储液器。
式I化合物的施用剂量(以式A化合物计)将取决于接受者的年龄、健康和体重,联用药物的种类,治疗频率,给药途径等。药物可以单一日剂量施用,每天给药一次、每两天给药一次、每三天给药一次、每四天给药一次,或者总日剂量以每天两次、三次或四次的分开剂量施用。式I化合物用药量(以式I化合物计)为0.01-100mg/kg/天,优选为0.1-10mg/kg/天,例如为0.5mg/kg/天,1mg/kg/天、2mg/kg/天、5mg/kg/天等等。
所述药物组合物可以和其他的治疗剂联合应用给药或者制成组合药物。所述其他治疗剂根据疾病和病症类型不同,可以是其他的治疗癌症的药物等。
其他的治疗癌症的药物包括但不限于:紫杉类(多西他赛、紫杉醇)、铂类(奥沙利铂、顺铂)、氟尿嘧啶类(希罗达、替吉奥)、蒽环类(多柔吡星、吡柔吡星)、吉菲替尼、索拉菲尼、抗生素、血容量扩充剂、血管活性药物、糖皮质激素、血制品、血糖控制药物、抗凝药等。
本发明提供式I化合物在制备治疗或预防癌症的药物中的应用。所述药物能够抑制肿瘤生长、加速细胞凋亡和抑制细胞活力。
本发明提供式I化合物和其他的治疗癌症的药物联合在制备治疗或预防癌症的药物中的用途。
本发明提供式I化合物和其他的治疗癌症的药物联合在制备抑制癌症患者的肿瘤生长的药物中的用途。
本发明提供式I化合物和其他的治疗癌症的药物联合在制备加速癌症患者的肿瘤细胞凋亡的药物中的用途。
本发明提供式I化合物和其他的治疗癌症的药物联合在制备抑制癌症患者的肿瘤细胞活力的药物中的用途。
本发明提供式I化合物在制备和其他的治疗癌症的药物联合治疗或预防癌症药物中的用途。
本发明提供一种治疗或预防癌症,抑制肿瘤生长、加速细胞凋亡和抑制细胞活力的方法,其特征在于,对有需要的患者施用治疗有效量的式I化合物或其溶剂化物、或者含有式I化合物或其溶剂化物的药物组合物。
本发明式I化合物具有明确且高效的癌症治疗和预防效果,能够抑制肿瘤生长、加速细胞凋亡和抑制细胞活力,不具有细胞毒性。因此在治疗用途的同时保证用药的安全性。式I化合物结构明确,利于制备和质量控制。
附图说明
图1CCK-8检测HCT-8细胞活力实验结果
图2CCK-8检测HCT116细胞活力实验结果
具体实施方式
下文将结合具体实施例对本发明的技术方案做更进一步的详细说明。应当理解,下列实施例仅为示例性地说明和解释本发明,而不应被解释为对本发明保护范围的限制。凡基于本发明上述内容所实现的技术均涵盖在本发明旨在保护的范围内。
除非另有说明,以下实施例中使用的原料和试剂均为市售商品,或者可以通过已知方法制备。
PCC:氯铬酸吡啶盐;(dppf)2PdCl2:[1,1'-双(二苯基膦基)二茂铁]二氯化钯;Pd(OAc)2:醋酸钯;Pd/C:钯碳;PPh3:三苯基磷;TBAB:四丁基溴化铵;NaBH4:硼氢化钠;BPPO:N1,N2双([1,1'-联苯]-2-基)乙二酰胺;TMSBr:三甲基溴硅烷;(COCl)2:草酰氯;TFA:三氟乙酸;DMF:N,N-二甲基甲酰胺;Pd(PPh3)4:四三苯基膦钯。
实施例1 Ra系列化合物的制备
1、肉桂酸(Ra1)的制备方法
在室温下,50mL DMF中依次加入苯甲醛(5.00mL,49.06mmol)、丙二酸(15.32g,147.31mmol)以及吡啶(4.00mL,49.72mmol)。95℃搅拌过夜后TLC监测,待反应完全后用饱和NaHCO3溶液/二氯甲烷体系萃取。收集有机层后加入过量无水硫酸钠干燥,随后过滤并减压浓缩,经硅胶柱色谱法纯化(石油醚:乙酸乙酯=2:1,体积比),得到白色固体肉桂酸(Ra1)(6.71g,92%)。
1H NMR(400MHz,CDCl3)δ12.07(bs,1H),7.80(d,J=16.0Hz,1H),7.58–7.51(m,2H),7.42–7.36(m,3H),6.46(d,J=16.0Hz,1H).13C NMR(100MHz,CDCl3)δ172.86,147.25,134.16,130.88,129.09(2C),128.51(2C),117.48.
实施例2 Rb系列化合物的制备
1、(3-(苯氧基甲基)苯基)甲醇(Rb2)的制备方法
将间溴甲基苯甲酸甲酯(2.01g,8.77mmol),苯酚(0.98g,10.41mmol),TBAB(1.40g,4.35mmol)以及磷酸钾(2.80g,13.19mmol)依次加入到100mL圆底烧瓶中,加入纯水(10mL)作溶剂,室温搅拌24h。TLC监测反应结束后,0℃下加入饱和NaHCO3溶液碱化反应液,用DCM与饱和NaCl溶液萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法进行分离纯化(石油醚:乙酸乙酯=30:1),减压浓缩,得到白色粉末状化合物Rb2-1(2.08g,98%)。
1H NMR(400MHz,CDCl3)δ8.10(s,1H),7.98(d,J=7.7Hz,1H),7.60(d,J=7.6Hz,1H),7.43(s,1H),7.27(t,J=7.8Hz,2H),6.95–6.93(m,3H),5.05(s,2H),3.89(s,3H).13CNMR(100MHz,CDCl3)δ166.88,158.61,137.65,131.89,130.56,129.59,129.16,128.73,128.55,121.21,114.91,69.35,52.18.
将化合物Rb2-1(0.65g,2.70mmol),氯化锂(0.11g,2.60mmol)加入到100mL圆底烧瓶中,加入THF(10mL)将其溶解,0℃下缓慢加入硼氢化钠(0.61g,17.02mmol)的THF溶液,65℃下加热回流15min,加入甲醇(8mL),65℃下反应3h。TLC监测反应结束后,冷却至室温,加入饱和NH4Cl溶液(10mL)淬灭反应,用DCM与饱和NaCl溶液进行萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法分离纯化(石油醚:乙酸乙酯=3:1),减压浓缩,得到白色粉末状化合物(3-(苯氧基甲基)苯基)甲醇(Rb2)(0.54g,94%)。
1H NMR(400MHz,CDCl3)δ7.38(s,1H),7.33(s,2H),7.28–7.26(m,3H),6.95(t,J=7.2Hz,3H),5.03(s,2H),4.62(s,2H),3.78(s,1H).13C NMR(100MHz,CDCl3)δ158.77,141.36,137.43,129.56,128.84,126.77,126.58,126.04,121.07,114.90,69.85,65.08.
2、(3-(3-氟苯氧基)苯基)甲醇(Rb4)的制备方法
Rb3-Rb6为同一系列的结构类似物,可按照相似方法合成获得,以Rb4为例详述其制备方法:
依次取3-羟基苄醇(1.00g,8.06mmol)、间溴氟苯(1.35mL,12.09mmol)、BPPO(0.03g,0.08mmol)、K3PO4(3.42g,16.13mmol)以及CuI(0.02g,0.10mmol)于100mL三颈烧瓶中并加入20mL DMF溶解,Ar2保护,90℃搅拌过夜,TLC监测,反应停止后应用乙酸乙酯/饱和食盐水体系萃取,收集有机层后加入过量无水硫酸钠干燥0.5h随后过滤并减压浓缩,经硅胶柱色谱法纯化(石油醚:乙酸乙酯=20:1),得到无色液体状(3-(3-氟苯氧基)苯基)甲醇(Rb4)(0.50g,28%),。
1H NMR(400MHz,CDCl3)δ7.30(t,J=7.9Hz,1H),7.23(td,J=8.3,6.7Hz,1H),7.09(d,J=7.6Hz,1H),7.00(t,J=2.0Hz,1H),6.92(dd,J=8.1,2.5Hz,1H),6.79-6.74(m,2H),6.67(dt,J=10.2,2.4Hz,1H),4.60(s,2H),2.66(bs,1H).13C NMR(100MHz,CDCl3)δ158.84,158.73,156.62,143.23,130.63,130.53,130.08,122.39,118.53,117.81,114.15,114.12,64.65.
3、Rb7和Rb8的制备方法
1)Rb7的制备
依次取3-溴苯甲醇(1.40mL,11.68mmol)、N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯(3.00g,9.71mmol)、(dppf)2PdCl2(0.07g,96.99μmol)以及K3PO4(6.17g,29.10mmol)于50mL三颈烧瓶中并加入20mL 二氧六环与水的混合溶液(二氧六环:水=4:1)溶解,Ar2保护,80℃搅拌4h,TLC监测,反应完毕后应用二氯甲烷/饱和食盐水体系萃取,收集有机层后加入过量无水硫酸钠干燥0.5h随后过滤并减压浓缩,经硅胶柱色谱法纯化(石油醚:乙酸乙酯=10:1,体积比),得到无色液体状3-(4-(1-叔丁氧羰基-2,3,6-三氢吡啶基))苄醇(Rb7)(2.30g,82%)。
1H NMR(400MHz,CDCl3)δ7.38–7.29(m,2H),7.16(t,J=7.9Hz,1H),7.11(d,J=7.9Hz,1H),4.23(s,2H),2.77(t,J=12.8Hz,2H),2.60(td,J=12.2,3.3Hz,1H),1.85–1.71(m,2H),1.65–1.51(m,2H),1.51–1.40(m,9H).13C NMR(100MHz,CDCl3)δ154.86,148.19,130.20,130.08,129.53,125.56,122.68,79.62,44.42,42.56,33.10,28.58(3C).
2)Rb8的制备
取化合物Rb7(0.50g,1.73mmol)以及10%的Pd/C(0.05g)于50mL三颈烧瓶中,加入20mL乙酸乙酯溶解,经重复换气后接入氢气球,室温搅拌过夜,TLC监测,反应完全后垫硅藻土过滤,减压浓缩后上柱,经硅胶柱色谱法纯化后得到3-(4-(1-叔丁氧羰基)哌啶基)苄醇(Rb8)(0.49g,97%)。
1H NMR(400MHz,CDCl3)δ7.19(t,J=7.8Hz,1H),7.06–6.91(m,3H),4.24(s,2H),2.78(t,J=13.5Hz,2H),2.60(tt,J=12.1,3.6Hz,1H),2.33(s,3H),1.82(d,J=3.6Hz,1H),1.79(d,J=3.3Hz,1H),1.61(qd,J=12.7,4.3Hz,2H),1.48(s,9H).13C NMR(100MHz,CDCl3)δ154.86,148.19,130.20,130.08,129.53,125.56,122.68,79.62,44.13,42.56(2C),33.10,28.58(3C).
4、(3-甲氧基-5-(苯氧基甲基)苯基)甲醇(Rb9)的制备方法
1)Rb9-1的制备
将5-甲氧基-异邻苯二甲酸甲酯(0.63g,2.81mmol)放置于100mL圆底烧瓶中,加入甲醇(10mL)使其溶解,0℃下滴加硼氢化钠(1.12g,29.60mmol)的甲醇溶液,室温下反应4h。TLC监测反应结束后,在0℃下,加入饱和NH4Cl溶液淬灭硼氢化钠,用DCM与饱和NaCl溶液进行萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法分离纯化(石油醚:乙酸乙酯=5:1),通过旋转蒸发仪进行减压浓缩,得到白色粉末状化合物Rb9-1(0.39g,71%)。
1H NMR(400MHz,CDCl3)δ7.55(s,1H),7.41(s,1H),7.08(s,1H),4.65(s,2H),3.88(s,3H),3.81(s,3H),3.10(s,1H).13C NMR(100MHz,CDCl3)δ167.06,159.61,143.00,131.16,120.09,117.43,113.04,64.14,55.36,52.18.
2)Rb9-2的制备
将化合物Rb9-1(0.4mL,2.37mmol)加入到5mL茄形瓶中,加入三甲基溴硅烷(0.7mL,5.01mmol),室温下反应12h。TLC监测反应结束后,直接通过柱层析色谱法进行分离纯化(石油醚:乙酸乙酯=50:1),减压浓缩,得到淡黄色油状化合物Rb9-2(0.61g,99%)。
1H NMR(400MHz,CDCl3)δ7.66(s,1H),7.49(s,1H),7.12(s,1H),4.47(s,2H),3.92(s,3H),3.85(s,3H).13C NMR(100MHz,CDCl3)δ166.39,159.84,139.42,131.96,122.47,119.78,114.27,55.61,52.32,32.47.
3)Rb9-3的制备
将化合物Rb9-2(0.62g,2.39mmol),苯酚(0.26g,2.76mmol),TBAB(0.37g,1.15mmol)以及磷酸钾(0.73g,3.42mmol)按顺序加入到100mL圆底烧瓶中,加入纯水(15mL)作溶剂,室温反应24h。TLC监测反应结束后,0℃下加入饱和Na2CO3溶液碱化反应液,用DCM与饱和NaCl溶液进行萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法分离纯化(石油醚:乙酸乙酯=20:1),通过旋转蒸发仪进行减压浓缩,得到白色化合物Rb9-3(0.52g,80%)。
1H NMR(400MHz,CDCl3)δ7.70(s,1H),7.51(s,1H),7.28(t,J=7.9Hz,2H),7.19(s,1H),6.97–6.95(m,3H),5.05(s,2H),3.91(s,3H),3.84(s,3H).13C NMR(100MHz,CDCl3)δ166.88,159.93,158.56,139.12,131.71,129.56,121.21,120.82,120.52,118.27,115.36,114.92,113.66,69.29,55.56,52.28.
4)Rb9的制备
将化合物Rb9-3(0.50g,1.84mmol),氯化锂(0.08g,1.89mmol)加入到100mL圆底烧瓶中,用THF(5mL)使其溶解,0℃下缓慢加入硼氢化钠(0.72g,19.0mmol)的THF溶液,70℃下加热回流15min,加入甲醇(3mL),继续在70℃下下反应12h。TLC监测反应结束后,室温冷却,加入饱和NH4Cl溶液(10mL)淬灭反应,用DCM与饱和NaCl溶液进行萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法进行分离纯化(石油醚:乙酸乙酯=30:1),减压浓缩,得到白色粉末状化合物Rb9(0.30g,67%)。
1H NMR(400MHz,CDCl3)δ7.26(t,J=7.7Hz,2H),6.99–6.89(m,4H),6.87(s,1H),6.83(s,1H),4.97(s,2H),4.59(s,2H),3.76(s,3H),2.53(s,1H).13C NMR(100MHz,CDCl3)δ160.12,158.75,142.99,138.93,129.54,121.08,118.03,114.92,112.22,111.80,69.77,64.95,55.34.
5、(3-(2,6-二氟苯氧基)苯基)甲醇(Rb10)的制备方法
依次取3-羟基苄醇(1.00g,8.06mmol)、1-溴-2,6-二氟苯(1.36mL,12.05mmol)、BPPO(0.03g,0.08mmol)、K3PO4(3.42g,16.13mmol)以及CuI(0.02g,0.11mmol)于100mL三颈烧瓶中并加入20mL DMF溶解,Ar2保护,90℃搅拌过夜,TLC监测,反应停止后应用乙酸乙酯/饱和食盐水体系萃取,收集有机层后加入过量无水硫酸钠干燥0.5h随后过滤并减压浓缩,经硅胶柱色谱法纯化(石油醚:乙酸乙酯=20:1,体积比),得到(3-(2,6-二氟苯氧基)苯基)甲醇(Rb10)(0.27g,14%),无色液体。
1H NMR(400MHz,CDCl3)δ7.27(t,J=7.9Hz,1H),7.14(td,J=8.3,6.2Hz,1H),7.07(d,J=7.6Hz,1H),6.95(s,1H),6.90–6.77(m,2H),6.65(dt,J=8.3,1.3Hz,1H),4.62(s,2H),1.65(bs.,1H).19F NMR(376MHz,CDCl3)δ-104.51.13C NMR(100MHz,CDCl3)δ156.84,143.35,130.19,128.77,128.68,122.37,117.78,116.95,115.42,115.39,111.60,111.37,64.95.
实施例3化合物1-15的制备方法
1、化合物1和2的制备
1)(E)-(3-苯氧基甲基)肉桂酸苄酯(化合物1)的制备
取化合物Ra1(0.50g,3.38mmol)于烘干的50mL圆底烧瓶中,加入20mL无水DCM溶解,滴入1滴干燥的DMF做催化剂,冰浴并缓慢加入草酰氯(0.25mL,2.95mmol)搅拌反应40min,TLC监测,待反应完全后加入干燥的三乙胺(0.70mL,5.05mmol)以及Rb2(0.52mL,2.76mmol),室温反应1h,反应完全后加水(5mL)淬灭,二氯甲烷/饱和食盐水体系萃取,收集有机层后加入过量无水硫酸钠干燥0.5h随后过滤并减压浓缩,经硅胶柱色谱法纯化,得到白色固体(E)-(3-苯氧基甲基)肉桂酸苄酯(化合物1)(0.89g,两步产率94%)。
1H NMR(400MHz,CDCl3)δ7.73(d,J=16.0Hz,1H),7.54–7.46(m,3H),7.41–7.38(m,2H),7.38–7.35(m,4H),7.28(t,J=8.0Hz,2H),7.01–6.92(m,3H),6.48(d,J=16.0Hz,1H),5.26(s,2H),5.07(s,2H).13C NMR(100MHz,CDCl3)δ166.77,158.77,145.30,137.62,136.54,134.41,130.41,130.29,129.55(2C),128.94(2C),128.17(2C),127.84(2C),127.37,127.28,121.09,117.88,114.91,69.73,66.19.
2)(E)-3-甲氧基-(5-苯氧基甲基)肉桂酸苄酯(化合物2)的制备
合成步骤同化合物1,即Ra1和草酰氯反应生成的酰氯化合物再与Rb9反应最终获得(E)-3-甲氧基-(5-苯氧基甲基)肉桂酸苄酯(化合物2)(0.14g,两步产率93%)。
1H NMR(400MHz,CDCl3)δ7.73(d,J=16.0Hz,1H),7.56–7.47(m,2H),7.42–7.33(m,3H),7.32–7.24(m,2H),7.06(s,1H),7.01–6.92(m,4H),6.90(s,1H),6.49(d,J=16.0Hz,1H),5.23(s,2H),5.04(s,2H),3.82(s,3H).13C NMR(100MHz,CDCl3)δ166.73,160.12,158.72,145.33,139.88,139.12,138.85,137.93,137.21,134.38,131.54,130.41,129.53,128.93,128.16,121.09,119.30,117.83,114.90,113.25,112.74,69.66,66.09,55.40.
2、化合物3-6的制备
化合物3-6的合成方法与化合物1相似,Ra1酰氯化后分别与Rb4、Rb5、Rb6和Rb10反应生成对应的(E)-3-(3-氟苯氧基)肉桂酸苄酯(化合物3)、(E)-3-(4-氟苯氧基)肉桂酸苄酯(化合物4)、(E)-3-(2-氟苯氧基)肉桂酸苄酯(化合物5)和(E)-3-(2,6-二氟苯氧基)肉桂酸苄酯(化合物6)。
1)(E)-3-(3-氟苯氧基)肉桂酸苄酯(化合物3)的制备
合成步骤同化合物1,得到(E)-3-(3-氟苯氧基)肉桂酸苄酯(化合物3)(0.98g,两步产率96%),为白色固体。
1H NMR(400MHz,CDCl3)δ7.72(d,J=16.0Hz,1H),7.52-7.41(m,2H),7.37-7.31(m,4H),7.23(dd,J=15.3,7.7Hz,1H),7.17(d,J=7.6Hz,1H),7.09(s,1H),6.97(d,J=8.1Hz,1H),6.76(t,J=7.1Hz,2H),6.74–6.67(m,1H),6.47(d,J=16.0Hz,1H),5.21(s,2H).13CNMR(100MHz,CDCl3)δ166.64,156.66,145.43,138.48,134.36,130.67,130.57,130.48,130.16,128.96,128.21,123.58,119.05,119.02,117.74,114.22,114.19,110.25,110.04,106.42,106.18,65.73.
按照此方法也可获得(E)-3-(4-氟苯氧基)肉桂酸苄酯(化合物4)和(E)-3-(2-氟苯氧基)肉桂酸苄酯(化合物5)。
2)(E)-3-(2,6-二氟苯氧基)肉桂酸苄酯(化合物6)的制备
合成步骤同化合物1,获得白色固体(E)-3-(2,6-二氟苯氧基)肉桂酸苄酯(化合物6)(0.97g,两步产率90%)。
1H NMR(400MHz,CDCl3)δ7.64(d,J=16.0Hz,1H),7.44(d,J=3.0Hz,2H),7.33–7.29(m,3H),7.17(d,J=4.6Hz,1H),7.12(t,J=8.3Hz,2H),6.99(s,1H),6.89–6.80(m,2H),6.65(d,J=8.3Hz,1H),6.40(d,J=16.0Hz,1H),5.15(s,2H).19F NMR(376MHz,CDCl3)δ-104.42.13CNMR(100MHz,CDCl3)δ166.79,156.73,145.59,138.54,134.42,130.59(2C),130.25(2C),129.07,128.80,128.70(2C),128.29(2C),123.62,118.27,117.77,115.35,111.66,111.44,65.79.
3、化合物7-10的制备
1)(E)-3-(4-(1-叔丁氧羰基-2,3,6-三氢吡啶基))肉桂酸苄酯(化合物7)和(E)-3-(4-(1-叔丁氧羰基哌啶基))肉桂酸苄酯(化合物9)的制备
化合物7和化合物9的合成步骤与化合物1相似,Ra1酰氯化后分别与Rb7、Rb8反应生成对应的(E)-3-(4-(1-叔丁氧羰基-2,3,6-三氢吡啶基))肉桂酸苄酯(化合物7)和(E)-3-(4-(1-叔丁氧羰基哌啶基))肉桂酸苄酯(化合物9)。
合成步骤同化合物1,获得白色固体(E)-3-(4-(1-叔丁氧羰基-2,3,6-三氢吡啶基))肉桂酸苄酯(化合物7)(1.17g,两步产率95%)。
1H NMR(400MHz,CDCl3)δ7.72(d,J=16.0Hz,1H),7.54–7.45(m,2H),7.42(s,1H),7.35-7.29(m,6H),6.48(d,J=16.0Hz,1H),6.04(s,1H),5.24(s,2H),4.16–3.97(m,2H),3.62(t,J=5.8Hz,2H),2.61–2.44(m,2H),1.50(s,9H).13C NMR(100MHz,CDCl3)δ166.57,154.70,145.11,144.85,142.24,141.00,136.17,134.22,130.27,129.32,128.79,128.60,128.02(2C),127.09,124.85,124.76,117.73,79.53,66.23,43.83,39.74,28.42(3C),27.32.
2)(E)-3-(4-(1,2,3,6-四氢吡啶基))肉桂酸苄酯(化合物8)和(E)-3-(4-哌啶基)肉桂酸苄酯(化合物10)的制备
化合物8和化合物10的合成步骤相同,均为脱除N-Boc保护基反应。
取化合物9(0.50g,1.19mmol)溶解于10mL DCM中,冰浴并缓慢加入三氟乙酸(1.33mL,17.91mmol),室温搅拌过夜,TLC监测,待反应完全后冰浴缓慢加入饱和NaHCO3溶液至pH为8左右,二氯甲烷/饱和食盐水体系萃取,收集有机层后加入过量无水硫酸钠干燥0.5h随后过滤并减压浓缩,经中性氧化铝柱色谱法纯化(DCM:(10甲醇:1氨水)=8:1,体积比),得到白色固体(E)-3-(4-哌啶基)肉桂酸苄酯(化合物10)(0.33g,87%)。
1H NMR(400MHz,CDCl3)δ7.69(d,J=15.4Hz,1H),7.52(d,J=7.1Hz,2H),7.35(d,J=7.9Hz,3H),7.19(t,J=7.6Hz,1H),7.08–6.89(m,4H),4.88(d,J=12.9Hz,1H),4.22(d,J=13.2Hz,1H),3.18(t,J=13.6Hz,1H),2.84–2.63(m,2H),2.32(s,3H),1.91(d,J=13.2Hz,2H),1.79–1.59(m,2H),1.27(d,J=10.0Hz,1H).13C NMR(100MHz,CDCl3)δ165.43,145.16,142.49,138.12,135.44,129.51,128.79,128.49,127.74,127.57,127.27,123.78,117.63,46.66,43.10,42.86,34.15,32.99,29.71,29.67,21.49.
4、化合物11的制备
合成步骤同化合物1,获得(3-苯氧基苄基)-3-苯基丙酸酯(化合物11)(0.95g,产率98%)。
1H NMR(400MHz,CDCl3)δ7.32(t,J=7.9Hz,2H),7.29–7.21(m,3H),7.17(t,J=7.1Hz,3H),7.11–7.10(m,1H),7.00(d,J=7.9Hz,3H),6.97–6.90(m,2H),5.06(s,2H),2.95(t,J=7.8Hz,2H),2.67(t,J=7.7Hz,2H).13C NMR(100MHz,CDCl3)δ172.64,157.57,156.96,140.39,139.76,137.98,137.23,129.94,129.86,128.57,128.34,126.36,123.54,123.28(2C),122.71,119.12,118.41,118.29,65.81,35.91,30.98.
5、化合物12和化合物13的制备
1)(E)-(3-苯氧基)-4-甲氧基肉桂酸苄酯(化合物12)的制备
将间苯氧基苄醇(2.6mL,15mmol)放置于干燥的100mL圆底烧瓶中,加入超干二氯甲烷(20mL)使其完全溶解,0℃下依次滴加乙酸酐(1.7mL,18mmol)和无水三乙胺(6.3mL,45mmol),在室温下反应4h。TLC监测反应结束后,用DCM与饱和NaCl溶液萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法分离纯化(洗脱剂为石油醚:乙酸乙酯=10:1),减压浓缩,得到白色粉末状化合物12-1(3.18g,89%)。
将化合物11-1(0.27g,1.11mmol),大茴香醛(0.10g,0.73mmol),三乙胺(0.3mL,2.22mmol)加入到50mL圆底烧瓶中,加入二氯甲烷使之溶解,在室温下反应40min后,加入四氯化钛(1.5mL,13.99mmol),室温继续反应5h。TLC监测反应结束后,用DCM与饱和NaCl溶液萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法分离纯化(洗脱剂为石油醚:乙酸乙酯=8:1),减压浓缩,得到白色粉末状(E)-(3-苯氧基)-4-甲氧基肉桂酸苄酯(化合物12)(0.23g,87%)。
1H NMR(400MHz,CDCl3)δ7.67(d,J=15.9Hz,1H),7.46(d,J=7.9Hz,2H),7.37–7.28(m,3H),7.14–7.09(m,2H),7.07(s,1H),7.02(d,J=8.2Hz,2H),6.95(d,J=8.1Hz,1H),6.89(d,J=7.9Hz,2H),6.34(d,J=15.9Hz,1H),5.20(s,2H),3.81(s,3H).13C NMR(100MHz,CDCl3)δ167.04,161.53,158.23,157.59,157.00,138.67,138.33,137.76,129.96(2C),129.87,127.09,123.51(2C),122.75,121.23,119.12,119.05,118.36,115.20,114.39,65.70,55.39.
2)(E)-(3-苯氧基)-3,4-二甲氧基肉桂酸苄酯(化合物13)的制备
合成步骤同化合物12,获得(E)-(3-苯氧基)-3,4-二甲氧基肉桂酸苄酯(化合物13)(0.21g,产率为91%)。
1H NMR(400MHz,CDCl3)δ7.66(d,J=15.9Hz,1H),7.34(d,J=6.8Hz,3H),7.13–7.11(m,4H),7.06–7.02(m,2H),7.01(s,1H),6.95(d,J=8.1Hz,1H),6.86(d,J=8.2Hz,1H),6.35(d,J=15.9Hz,1H),5.21(s,2H),3.90(s,6H).13C NMR(100MHz,CDCl3)δ166.88,157.56,156.97,151.27,149.27,145.22,138.24,129.92,129.81(2C),127.35,123.46,122.76,122.72,119.05(2C),118.35(2C),115.43,111.08,109.69,65.71,55.98,55.90.
5、化合物14-16的制备
1)(E)-2-(4-吡啶基)肉桂酸叔丁酯(化合物14)的制备
将4-溴吡啶(7.00g,44.60mmol),2-甲酰基苯硼酸(6.52g,43.47mmol),碳酸钠(7.63g,71.98mmol),四三苯基膦钯(2.69g,2.33mmol)加入到100mL双颈圆底烧瓶中,加入THF的水溶液(THF:H2O=4:1,20mL),在90℃下冷凝回流,反应过夜。TLC监测反应结束后,室温冷却,垫硅藻土过滤,用DCM与饱和NaCl溶液萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法分离纯化(洗脱剂为石油醚:乙酸乙酯=5:1),通过旋转蒸发仪进行减压浓缩,得到白色粉末状化合物14-1(6.92g,87%)。
将化合物14-1(0.27g,1.47mmol),大茴香醛(0.10g,0.86mmol),三乙胺(0.3mL,2.22mmol)加入到50mL圆底烧瓶中,加入二氯甲烷使之溶解,在室温下反应40min后,加入四氯化钛(1.5mL,13.99mmol),室温继续反应5h。TLC监测反应结束后,用DCM与饱和NaCl溶液萃取,收集DCM层,加入无水Na2SO4干燥,过滤,收集滤液并浓缩。通过柱层析色谱法分离纯化(洗脱剂为石油醚:乙酸乙酯=8:1),减压浓缩,得到白色粉末状化合物(E)-2-(4-吡啶基)肉桂酸叔丁酯(化合物14)(0.23g,95%)。
1H NMR(400MHz,CDCl3)δ8.67(s,2H),7.72(d,J=5.9Hz,1H),7.56(d,J=15.8Hz,1H),7.44(d,J=3.2Hz,2H),7.34(s,1H),7.27(s,2H),6.36(d,J=15.9Hz,1H),1.48(s,9H).13CNMR(100MHz,CDCl3)δ165.81,149.73,149.13,147.91,141.20,140.89,139.78,132.62,130.01,129.85,128.83,126.97,124.64,122.17,80.64,28.15(3C).
2)(E)-2-(4-吡啶基)肉桂酸苄酯(化合物15)的制备
合成步骤同化合物14,获得(E)-2-(4-吡啶基)肉桂酸苄酯(化合物15)(0.26g,76%)。
1H NMR(400MHz,CDCl3)δ8.68(d,J=3.1Hz,2H),7.73–7.69(m,2H),7.52–7.40(m,2H),7.34(d,J=5.1Hz,5H),7.25(d,J=4.7Hz,3H),6.46(d,J=15.9Hz,1H),5.20(s,2H).13CNMR(100MHz,CDCl3)δ166.23,149.70,149.68,147.83,142.97,139.92,135.97,132.43,130.24,130.08,128.97,128.60,128.27(2C),128.13(2C),127.13,124.67,120.01,66.34,29.71.
3)(E)-(3-苯氧基)-2-(4-吡啶基)肉桂酸苄酯(化合物16)的制备
合成步骤同化合物14,获得(E)-(3-苯氧基)-2-(4-吡啶基)肉桂酸苄酯(化合物16)(0.34g,76%)。
1H NMR(400MHz,CDCl3)δ8.67(d,J=5.9Hz,2H),7.71–7.68(m,2H),7.47–7.44(m,2H),7.33–7.28(m,4H),7.27–7.25(m,2H),7.12–7.07(m,2H),7.01(d,J=7.8Hz,3H),6.95–6.93(m,1H),6.46(d,J=15.9Hz,1H),5.17(s,2H).13C NMR(100MHz,CDCl3)δ166.15,158.23,159.43,149.78(2C),147.77,143.14(2C),139.96,138.00,132.40,130.29,130.11(2C),129.94,128.97,127.17(2C),124.65,123.49,122.60,119.86,119.06(2C),118.38,118.27,65.84.
实施例4 CCK-8细胞活力检测实验
初步活性筛选后选取化合物14进行后续活性检测实验。选用HCT-8和HCT116两种结直肠癌细胞系并采用CCK-8试剂盒进行细胞活力检测实验,为探讨化合物14对HCT-8和HCT116的细胞活力及增殖的影响,用不同浓度的化合物14或5-氟脲嘧啶(5-FU,阳性药)作用于HCT-8和HCT116细胞24h,实验方法如下:
1)复苏HCT-8和HCT116细胞并培养至三代以上,PBS冲洗细胞两次后,使用胰蛋白酶消化细胞并离心,随后进行细胞计数。
2)将细胞以每孔约1x104个细胞的密度接种于96孔板上(100μl/孔),并将其放入培养箱中培养过夜。
3)预培养结束后,向96孔板中加入不同浓度(0、10、20、30、40、50μM)的化合物14,孵育24h。
4)共孵育结束后,向96孔板中加入CCK-8溶液(10μl/孔)。
5)将96孔板在培养箱中孵育1-4h。
6)用酶标仪测定在450nm处的吸光度,并计算细胞活力,公式如下:
细胞活力(%)=(加药OD-空白OD)/(对照OD-空白OD)
加药OD:含有细胞、CCK-8和化合物34孔位的吸光度
空白OD:含有培养基、CCK-8孔位的吸光度
对照OD:含有细胞、CCK-8孔位的吸光度。
表1-1试剂耗材及设备
实验结果如图1和图2所示,化合物14对结直肠癌细胞HCT-8和HCT116细胞的活力有抑制作用,呈浓度依赖性。我们观察到当给药浓度大于等于40μM时,给药24h后化合物18对HCT-8和HCT116细胞的存活率都有明显的抑制作用。例如,化合物14作用24h后,HCT-8细胞活力仅为46.07%,HCT116细胞活力仅为40.76%,与阳性对照药物5-氟尿嘧啶相比均有显著性差异。这些结果表明化合物14抑制了HCT-8和HCT116细胞的生长。
以上,对本发明的实施方式进行了说明。但是,本发明不限定于上述实施方式。凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (7)
1.具有式I结构的化合物,或者其立体异构体、药物可接受的盐或多晶型:
其中:
R1为苯环上的氢或取代基,R1为取代基时可相同或不同,独立的选自单取代或多取代,R1独立的选自氢、卤素、1-4个碳原子的烷基、1-4个碳原子的烷氧基、1-4个碳原子的卤代烷烃、1-4个碳原子的烷苯基、0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
R2和R3相同或不同,独立的选自氢、未取代或取代的苯基、萘基、蒽基、菲基,其中的取代基被独立地选自卤素、1-4个碳原子的烷基、1-4个碳原子的烷氧基、1-4个碳原子的卤代烷烃、1-4个碳原子的烷苯基、0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
R4独立的选自氢、甲基、二取代甲基、三取代甲基、未取代或取代的1-4个碳原子的烷苯基、萘基、蒽基、菲基,其中1-4个碳原子的烷苯基、萘基、蒽基、菲基的取代基被独立地选自卤素、1-4个碳原子的烷基、1-4个碳原子的烷氧基、1-4个碳原子的卤代烷烃、1-4个碳原子的烷苯基、0-4个碳原子的烷氧苯基或卤素等取代的0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
优选,R1为苯环上的氢或取代基,R1为取代基时选自单取代或二取代,R1选自氢、1-4个碳原子的烷氧基、1-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团;
优选,R2和R3相同,均选自氢;
优选,R4选自三取代甲基、未取代的1-4个碳原子的烷苯基或取代的1-4个碳原子的烷苯基,其中取代基被独立地选自1-4个碳原子的烷基、1-4个碳原子的烷氧基、0-4个碳原子的烷氧苯基或卤素等取代的0-4个碳原子的烷氧苯基、未取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物或被叔丁氧羰基等取代的包含氧氮硫的饱和或不饱和五元六元杂环化合物中的一个或更多个基团。
4.如权利要求1-3所述的化合物的合成方法。
5.一种药物组合物,其含有权利要求1-3所述的化合物、其药物可接受的盐或其溶剂合物;优选,所述药物组合物用于治疗或预防癌症,抑制肿瘤生长、加速细胞凋亡和抑制细胞活力;所述癌症包括原发性和继发性癌症,包括但不限于结直肠癌、肝癌、肺癌、淋巴癌和甲状腺癌等,优选,所述癌症为原发性结直肠癌。
6.根据权利要求5所述的药物组合物,其特征在于,进一步包含其他的治疗药物,所述其他治疗药物选自癌症治疗药物。
7.权利要求1-3所述的化合物或其溶剂合物在制备药物中的应用;优选,所述药物用于治疗或预防癌症,抑制肿瘤生长、加速细胞凋亡和抑制细胞活力;所述癌症包括原发性和继发性癌症,包括但不限于肝癌、肺癌、结肠癌、淋巴癌和甲状腺癌等,优选,所述癌症为结直肠癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211067689.0A CN115368239B (zh) | 2022-09-01 | 一种肉桂酸酯衍生物的合成及其制药应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211067689.0A CN115368239B (zh) | 2022-09-01 | 一种肉桂酸酯衍生物的合成及其制药应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115368239A true CN115368239A (zh) | 2022-11-22 |
CN115368239B CN115368239B (zh) | 2024-04-26 |
Family
ID=
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756527A (en) * | 1995-06-07 | 1998-05-26 | Ontogen Corporation | Imidazole derivatives useful as modulators of multi drug resistances |
US20070043043A1 (en) * | 2003-09-22 | 2007-02-22 | S*Bio Pte Ltd. | Benzimidazole derivates: preparation and pharmaceutical applications |
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756527A (en) * | 1995-06-07 | 1998-05-26 | Ontogen Corporation | Imidazole derivatives useful as modulators of multi drug resistances |
US20070043043A1 (en) * | 2003-09-22 | 2007-02-22 | S*Bio Pte Ltd. | Benzimidazole derivates: preparation and pharmaceutical applications |
Non-Patent Citations (2)
Title |
---|
"STN REGISTRY数据库公开记录", STN REGISTRY数据库公开记录, pages 1 - 8 * |
GOBEC STANISLAV 等: "Cinnamic acid esters as potent inhibitors of fungal 17β-hydroxysteroid dehydrogenase--a model enzyme of the short-chain dehydrogenase/reductase superfamily", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 15, pages 3933 - 3936 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016201328A1 (en) | Ezh2 inhibitors for treating lymphoma | |
US20220125788A1 (en) | FAK inhibitor and drug combination thereof | |
CN110590796B (zh) | 喜树碱衍生物及其制备方法和应用 | |
CN102134245B (zh) | 四氢异喹啉类化合物及其制备方法和用途 | |
WO2022095909A1 (zh) | 用作ntrk激酶抑制剂的化合物及其应用 | |
JP6021847B2 (ja) | 扁平上皮ガン及び肝ガンの抑制剤とされるスチルベノイド化合物及びその用途 | |
CN115368239A (zh) | 一种肉桂酸酯衍生物的合成及其制药应用 | |
CN112125914B (zh) | 5-取代的小檗胺衍生物,其制备方法和应用 | |
CN115368239B (zh) | 一种肉桂酸酯衍生物的合成及其制药应用 | |
AU2011274194B2 (en) | Phenyl nitrone compounds containing stilbene segment and use thereof | |
EP3369740A1 (en) | New cytidine derivative dimers and applications thereof | |
CN115551842B (zh) | 联苯类化合物 | |
CN115368263A (zh) | 一种肉桂酸酰胺衍生物的合成及其制药应用 | |
CN115010642B (zh) | β-榄香烯酰亚胺类衍生物及其应用 | |
CN104672136A (zh) | 1-取代菲基-n-烷基(酰基)-6,7-二甲氧基-1,2,3,4-四氢异喹啉衍生物及其制备方法和用途 | |
CN113929729B (zh) | 一种藜芦胺类化合物、其制备方法及其应用 | |
CN111138361B (zh) | 取代苯氧基-2-氮杂双环[3.2.1]辛烷类化合物及其制备方法和应用 | |
EP4284514A1 (en) | Heteroaromatic phosphonium salts and their use treating cancer | |
CN117447477A (zh) | 一种咪唑并四嗪类化合物、制备方法及其应用 | |
CN117185908A (zh) | 一种具有抗肿瘤活性的毛兰素衍生物、其药物组合物及用途 | |
CN117105948A (zh) | 一类二氘代喜树碱衍生物及制备方法 | |
CN112225737A (zh) | 具有hdac抑制活性的化合物、制备方法、组合物及用途 | |
KR102547925B1 (ko) | 암 치료를 위한 치료제로서의 4-옥소-n-(4-히드록시페닐)레틴아미드 유도체 | |
CN116217582A (zh) | 一种鹤氏唐松草碱衍生物及应用 | |
CN115381824A (zh) | 周期蛋白依赖性激酶9抑制剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |